Clinical trial
XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.
NCT05970302 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 7, 2023
- Completion date
- July 31, 2026
- Enrollment
- 52 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
bevacizumab, capecitabine, first-line, metastatic colorectal cancer (mcrc), mss/pmmr, oxaliplatin, ras-mutated, tislelizumab